

SUPPLEMENTARY TABLE 2 Complete response, complete control, and total response during delayed, overall, and acute phases of CINV among female patients (cisplatin stratum, mITT population)

Response, CINV phase	Arm, n (%)		Treatment difference (APF530-ondansetron) (95% CI), %	P value ^a
	APF530 500 mg SC (n = 51)	Ondansetron 0.15 mg/kg IV (n = 62)		
Complete response				
Delayed	32 (62.7)	31 (50.0)	12.7 (-5.4, 30.9)	.175
Overall	31 (60.8)	30 (48.4)	12.4 (-5.9, 30.7)	.188
Acute	42 (82.4)	45 (72.6)	9.8 (-5.5, 25.0)	.219
Complete control				
Delayed	30 (58.8)	30 (48.4)	10.4 (-7.9, 28.8)	.269
Overall	29 (56.9)	29 (46.8)	10.1 (-8.3, 28.5)	.286
Acute	42 (82.4)	43 (69.4)	13.0 (-2.5, 28.5)	.111
Total response				
Delayed	27 (52.9)	24 (38.7)	14.2 (-4.1, 32.5)	.130
Overall	27 (52.9)	24 (38.7)	14.2 (-4.1, 32.5)	.130
Acute	41 (80.4)	43 (69.4)	11.0 (-4.8, 26.9)	.181

CI, confidence interval; CINV, chemotherapy-induced nausea and vomiting; IV, intravenously; mITT, modified intent-to-treat; SC, subcutaneously

^aP values are based on the chi-square test.